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This article discusses the strengths and weaknesses of using sputum cytology, plain chest
radiograph and computerized tomography (CT) as screening modalities for lung cancer and
provides recommendations for screening.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Lung cancer is the second most common new cancer
diagnosis with an estimated 213,000 new cases in the United
States in 2007. More importantly, lung cancer is the leading
cause of cancer death for both men and women, accounting
for a staggering 29% (164,840) of all cancer deaths in the
United States. There are two major categories of lung
cancer: small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC). The vast majority (85–90%) of lung cancers
are NSCLCs. The 5-year relative survival rate for NSCLC is
49.5% when the disease is still localized and only 2.1% for
metastatic disease.1 Despite efforts at early detection and
new treatment modalities, the overall 5-year survival rate
remains only 15%.1 Many speculate that the poor survival
may be attributable to the indolent nature, thus resulting in
the symptomatic patient presenting late in the course of the
disease. Therefore, screening programs targeted to high-risk
individuals may offer earlier detection, thus increasingont matter & 2008 Elsevier Ltd. All rights reserved.
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kam).potentially curative treatment options and improving
patient survival.Historical perspective
To date, there have been several studies focused on early
detection of lung cancer. Sputum cytology and chest X-ray
have been proposed as modalities for lung cancer screen-
ing.2–6 In the 1970s, the National Cancer Institute (NCI)
sponsored randomized controlled trials (RCTs) at Johns
Hopkins, Memorial Sloan-Kettering Cancer Center and the
Mayo Clinic.3–6 The objectives of these trials were to
determine if the addition of sputum cytology to chest
X-ray interval examinations could lead to early detection of
lung cancer and if screening would reduce lung cancer
mortality. Approximately 31,000 men at high risk for lung
cancer, defined by an active or former history of smoking
one pack per day or more, were randomized to chest X-ray
with sputum cytology or chest X-ray alone. The baseline
screen, or ‘‘prevalence’’ screen, was followed by interval
screens over 5 years. Participants were then followed for
an additional 5 years thereafter. The prevalence screen
(or baseline screen) detected lung cancer in 0.5–0.8% of the
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many cases of lung cancer compared to cytology alone. Early
stage lung cancer detected with cytology alone were
predominantly centrally located squamous cell carcinomas
while those detected with chest X-ray alone were periph-
erally located adenocarcinomas. The dual approach of chest
X-ray with sputum analysis, however, detected only 23%
(7 out of 30) stage I lung cancer, as defined by the American
Joint Committee of Cancer (AJCC). The study demonstrated
that screening with chest X-ray and sputum cytology
resulted in the detection of early stage cancers suitable
for resection and therefore, translated to increased survi-
val.3–6 However, there was no difference in the number of
deaths in the screened population compared to the control
group. Therefore, screening with chest radiographs and/or
sputum cytology has not been recommended.
Over the last few years, the focus has shifted to the utility
of screening with low-dose computed tomography (CT).
Several studies have demonstrated that helical CT detects
more cases of early stage lung cancer than chest X-ray
and/or sputum cytology.7–10 In one study, investigators
detected 23 out of 25 cases of lung cancer by CT alone
compared to two cases detected by sputum cytology alone
(n ¼ 1520).10 However, the detection of early stage lung
cancer was also accompanied by a high rate of detecting
benign nodules.10 In another study, the proportion of lung
cancer detected by low-dose CT surpassed that of chest
X-ray and sputum cytology for the baseline screen as well as
for the repeat screen.8
Despite the ability to detect early stage disease, it is
unclear if screening studies will ultimately affect the overall
outcome of the disease. A retrospective review of patients
with pathologically proven NSCLC p3 cm in size found that
regardless of tumor size (o1 cm, 1–2 cm or 2–3 cm), the
stage distribution was comparable in all the patient groups
(i.e. the proportion of stage I lung cancer to stage IV lung
cancer was similar in all groups).11 Therefore, finding small
tumors by CT screening may not result in a stage shift, or
identification of lung cancer in the earlier stage of the
disease.12 A true stage shift should increase detection of
early stage disease with a concomitant decreased detection
of late stage disease. Unfortunately, this is yet to be
demonstrated. Therefore, substantial debate continues to
surround studies on CT screening for lung cancer, exempli-
fied more recently by two studies.Recent studies
From 1993 to 2005, the International Early Lung Cancer Action
Program (I-ELCAP) enrolled participants to determine the
utility of screening by spiral CT scanning.13 Participants were
asymptomatic men and women 40 years of age and older
deemed to be at risk for lung cancer because of either a history
of cigarette smoking, exposure to secondhand smoke or
occupational exposure (to asbestos, beryllium, uranium or
radon). A total of 31,567 participants underwent baseline CT
screening between 1993 and 2005. Of those, 27,456 partici-
pants underwent a repeat annual CTscreening approximately 1
year after the baseline screen. Investigators diagnosed lung
cancer in 484 participants: 405 cases were detected during the
baseline screen while 74 cases were detected during theannual screen. The remaining five cases were ‘‘interim’’
diagnoses, in which the baseline or annual screen was
negative, but further diagnostic work-up was pursued because
of suggestive symptoms or incidental findings. Approximately
85% (412 of 484) were found to have clinical stage I lung
cancer. Investigators followed all cases of lung cancer for a
median of 40 months (1–123 months). Deaths from lung cancer,
including deaths resulting from treatment of lung cancer, were
recorded and Kaplan–Meier curves were developed to estimate
the 10-year lung cancer-specific survival rates. The estimated
10-year survival rate for all participants diagnosed with lung
cancer, regardless of tumor stage and treatment, was
80%. Participants with stage I lung cancer had an estimated
10-year survival rate of 88%, and 92% if they underwent
surgical resection. These findings were a substantial improve-
ment compared to the 5-year survival rate of 60–80% quoted
by several studies for patients with pathological stage I disease
undergoing surgical resection.14 The authors concluded that
annual spiral CT screening of at-risk patients can detect lung
cancer that is curable. However, there were several limita-
tions. The study was a non-randomized, observational study
and the 10-year survival rate was extrapolated from a shorter
duration of follow-up (median of 40 months).
Recently, investigators15 conducted a study in which they
recruited 3246 asymptomatic current or former smokers for
screening with low-dose CT through three academic centers,
two in the United States and one in Italy. Participants
underwent a baseline CT scan followed by three to four
subsequent annual CT scans with a median follow-up of 3.9
years. The number of lung cancer events detected in the
cohort was compared to prediction models developed to
estimate the risk of being diagnosed with lung cancer or the
risk of dying from lung cancer. These models have been
described and validated in previous studies.16–18 The models
included individuals who are at high risk based on their age
(50–80 years of age), smoking history (average of 10–60
cigarettes per day over 25–60 years) and if former smokers,
how long they had quit (within the past 20 years).
The authors demonstrated a threefold increase in the
number of lung cancer diagnosed using low-dose CT screening,
and a 10-fold increase in the likelihood of undergoing
thoracic surgery for a lung lesion, as compared to the
validated prediction model. However, screening did not
reduce the number of advanced lung cancer diagnoses or
lung cancer deaths. They concluded that patients should not
undergo screening for lung cancer with low-dose CToutside of
clinical investigations until further conclusive data are
obtained. The authors acknowledged, however, that the
study was limited by its smaller sample size and that
perhaps, a longer duration of screening and/or follow-up
may have detected a benefit of screening. The study sample
size could not exclude a potential lung cancer mortality
reduction of 30% from screening.Limitations of screening
Studies on lung cancer screening have been met with varying
levels of criticism that are primarily based on the perceived
inherent biases in many studies. In order for screening to be
effective, the target disease should be a significant health
problem (resulting in substantial morbidity and mortality),
ARTICLE IN PRESS
E.J. Brawner et al.4should be detectable in those who are at risk before
symptoms occur, and earlier detection should result in
improved treatment outcomes. These requisites are cer-
tainly applicable to lung cancer. The screening test should
detect little ‘‘pseudodisease’’, or findings that are similar to
the target disease but do not represent it, should be cost-
effective and cause little morbidity.19,20
There are many aspects of screening as outlined by
Black.21 The natural history of disease includes preclinical
and clinical phases. Within the preclinical phase is the
detectable preclinical phase (DPCP) of the disease, wherein
a screening test begins to detect disease before signs or
symptoms arise. The critical point in the disease occurs
when therapy would be less effective. In the case of lung
cancer, this would be the advanced stages of the disease
when it is no longer localized and therefore carries a poorer
prognosis. Thus, if the DPCP occurs after that critical point,
then screening will not be applicable. An effective screening
modality would detect a target disease before it is clinically
apparent so that the development of advanced disease
is prevented.
There are certain biases that may affect screening tests.
The interval between diagnosis in an asymptomatic indivi-Preclinical Phase 
Detectable Preclinical Phase 
(DPCP)
Symptom onset 
Dx witho
Dx with screening
Figure 1 Lead time bias. Screening detects disease
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Detectable Preclinical Phase
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Symptom onset
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Aggressive disease
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Figure 2 Length time bias. Screening detects less aggdual and the development of signs and symptoms of disease
is known as the lead time. Lead time bias refers to
the relatively longer survival observed by earlier diagnosis
despite no change in death from lung cancer (see Figure 1).
Length time bias occurs when the length of the preclinical
stage of disease is longer than its clinical stage (e.g.
identifying a slow growing tumor). In other words, the
disease outcome may be the same if it was diagnosed later
as long as it was within the lengthened preclinical stage (see
Figure 2). Overdiagnosis bias refers to the diagnosis of
disease that otherwise would not have caused a patient’s
demise, such as less aggressive or indolent cancers, even if it
was not detected initially (see Figure 3). Overdiagnosed lung
cancers were previously defined by Yankelevitz et al.22 as
those having a volume doubling time (VDT) of 400 days.
Lindell et al.23 conducted a retrospective review of lung
cancers detected in high-risk individuals who underwent
annual chest CT screening for 5 years. ‘‘High-risk’’ indivi-
duals were defined as males or females aged 50 years or
older, with a smoking history of at least 20 pack years, no
prior history of cancer, no need for supplemental oxygen and
a life expectancy of at least 5 years. VDTwas also calculated
(based on a modified Schwartz equation) for cancers thatClinical Phase
ut screening
Lead
time
bias
earlier but the time of death remains unchanged.
Clinical Phase
screening
Clinical Phase
 (DPCP)
Symptom onset
screening
Length
time
bias
ressive disease due to its longer preclinical phase.
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Figure 3 Overdiagnosis bias. Screening detects indolent disease that may not become clinically significant (i.e. fatal).
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participants, 61 primary lung cancers were identified in 59
patients, most of which were non-bronchioloalveolar cell
adenocarcinomas. VDTwas calculated for 48 cancers with a
mean value of 518 days 71094 (median, 166 days; range
10–5810 days). The authors found that 27% (n ¼ 13) of these
cancers were calculated to have a VDT longer than 400 days.
Recalculated for stage I lung cancer only, 25% (n ¼ 10) would
be considered overdiagnosed. Interestingly, the mean tumor
VDTwas longer in women (688 days for women and 234 days
for men) and in almost every tumor histologic subtype, the
mean VDT was longer in women than in men. Thus, the
authors concluded that overdiagnosis may be substantial in
lung cancer screening, especially in women.
Lead time, length and overdiagnosis bias are the most
significant and widely appreciated biases that make survival
a less than ideal measure of screening benefit. The disease-
specific mortality, or the number of deaths in screened
participants attributed to lung cancer, is a better measure of
screening benefit than disease-specific survival since it
escapes these biases. Much debate on the impact of
overdiagnosis bias on the screening tests for lung cancer
remains.24–28 The true measure of overdiagnosis bias can
only be determined if all screened participants were
followed until death. This may not be completely feasible.
Prior studies have followed participants over a period of
time and there are a percentage of patients who are either
lost to follow-up or in which the cause of death is never
accurately determined.Risks of screening
Ideally, a screening test should detect little ‘‘pseudodi-
sease’’ and cause little morbidity. ‘‘Pseudodisease’’ refers to
findings that are similar to the target disease but do not
represent it, such as benign pulmonary nodules encountered
in screening for lung cancer. Pseudodisease may lead to
additional testing and surgical intervention accompanied by
further risk, expense and psychologic burden.
Crestanello et al.29 reviewed the number of thoracic
surgeries performed on 1520 participants screened with CT
from 1999 to 2002. Participants were at least 50 years of age
with a history of 20 pack years or greater. A total of 3130
indeterminate pulmonary nodules were detected in 73% of
the participants (n ¼ 1112) and 3.6% (n ¼ 55) underwent 60
thoracic operations. Lung cancer was diagnosed in 81.9%
(n ¼ 45) while benign disease was diagnosed in 18.1%
(n ¼ 10). The operative mortality was 1.7%; however, none
of the deaths occurred in those who underwent surgery for
benign disease. Nevertheless, this should be considered inthe context of the actual proportion of lung cancer
identified with screening, which only comprises 1.5% (45 of
3130) of the indeterminate pulmonary nodules detected.
The financial and economic implications of CT screening
are also of major concern. Estimates have ranged from
$2500 to as much as $2.3 million per life year gained.
Mahadevia et al.30 used a computer simulation program to
compare annual CT screening to no CT screening of 100,000
hypothetical patients. Adjusted for known biases and with a
projected stage shift of 50%, they estimated a cost of
$116,300 per quality-adjusted life year (QALY) gained for
current smokers and over $2.3 million per QALY gained for
former smokers. Chirikos et al.31 estimated the expected
economic value of screening by combining the projected
cost-effectiveness ratios and life expectancy (based on the
stage of lung cancer at diagnosis) of two hypothetical
cohorts. The authors determined that screening with CT
costs approximately $48,000 per life year gained if 50% of
lung cancer was detected at a localized stage. This cost
increased as smaller proportions of early stage lung cancer
were detected with CT screening. The lowest estimate of
cost-effectiveness analysis was published by Wisnivesky
et al.32 The authors incorporated data from the Early Lung
Cancer Action Project (ELCAP) into a decision analysis model
comparing CT screening in high-risk participants (X60 years
of age and X10 pack year smoking history) to observation
without screening. They found that a single baseline low-
dose CT screening cost $2500 per year of life saved and that
screening was expected to increase survival by 0.1 year at
an incremental cost of about $230. However, the cost of the
baseline low-dose CT screen exceeded $50,000 per year of
life saved if the likelihood of overdiagnosis bias was 450%.
Risks from radiation exposure have also been cause for
concern. The effective dose, or the absorbed energy non-
homogenously distributed within an organ in CT, is expressed
in sieverts (Sv). The National Council on Radiation Protec-
tion and Measurements (NCRP) quoted an average natural
(non-medical) radiation exposure per individual in the
United States of about 3mSv/year. Man-made sources of
radiation contribute another 0.6mSv, the majority of which
comes from medical X-rays (0.4mSv).33 The effective
dose equivalent with chest radiography ranges from 0.06
to 0.25mSv, 3–27mSv for conventional chest CT and
0.3–0.55mSv for low-dose CT.33 Thus, CT screening which
can include interval follow-up CT studies within a year can
exceed the average natural radiation exposure per indivi-
dual. What becomes of the cancer risk from radiation
exposure? This concern was brought to light more recently
with a publication in the New England Journal of Medicine.34
Our current knowledge of the risks of cancer from radiation
exposure come from the follow-up of atomic bomb survivors
ARTICLE IN PRESS
E.J. Brawner et al.6in Japan, spanning over 50 years.34,35 The authors note that
the survivors who were exposed to even lower radiation
doses (mean dose 40mSv) had an increased overall risk of
cancer. This implies that two or three conventional CT scans
in an adult could potentially equal or surpass 40mSv.34 The
authors, however, derived this conclusion chiefly from CT
studies obtained for diagnosis rather than for screening
purposes. Nevertheless, the concern remains.
Complementary modalities
The utility of F-18-fluorodeoxyglucose positron emission
tomography (FDG-PET) as an adjunct to spiral CT was
evaluated most recently by Bastarikka et al.36 F-18-
fluorodeoxyglucose is a radioactive tracer that accumulates
in lesions that have a high metabolism, such as rapidly
growing tumors. A total of 911 asymptomatic current or
former smokers were enrolled, the majority (76%) of which
were men who had a median smoking history of 30 pack
years. All participants received a baseline spiral CT screen.
Negative baseline studies were followed with a repeat
screening CT after 12 months. Non-calcified nodules
X10mm or smaller growing nodules (7mm) found on
baseline spiral CT screen were evaluated with FDG-PET.
Nodules that were positive on FDG-PET, defined by visual
analysis rather than standardized uptake value (SUV), were
assessed with percutaneous fine needle aspiration (FNA) or
an intraoperative biopsy. Nodules that were negative on
FDG-PET were followed with a repeat CT 3 months later.
Eleven NSCLC and one SCLC were diagnosed with the
baseline screen (prevalence rate of 1.32%). Two NSCLCs
were discovered on the annual screen (incidence rate of
0.47%). The sensitivity and specificity for diagnosing
malignancy were 69% and 91%, respectively. The positive
predictive value and negative predictive value for FDG-PET
were 90% and 71%, respectively. For nodules found to be
negative on FDG-PET followed by a 3 month repeat CT, the
negative predictive value was 100%. Lung cancer was
diagnosed 3 months earlier in 9 of 13 patients using FDG-
PET compared to short-term follow-up CT. Six PET-positive
nodules were followed by percutaneous FNA, which yielded
a diagnosis of lung cancer in four of the six cases. Thus, the
addition of FDG-PET to CT may streamline the work-up of
nodules detected on screening but may not completely
eliminate unnecessary invasive procedures. Further investi-
gations on FDG-PET have yet to be undertaken with
particular attention to its cost, radiation risk and possibly,
enhanced detection of ‘‘pseudodisease’’.
Future/ongoing studies
To date, studies investigating the effectiveness of CT
scanning in screening have largely been observational.
However, there are two current randomized trials that
may clarify the potential role for CT scans in lung cancer
screening. The National Lung Screening Trial (NLST) is a
multi-center RCT sponsored by the NCI, comparing the
effectiveness of helical CT versus chest X-ray in screening
individuals at high risk for lung cancer. The primary
objective of the study is to determine if CT screening can
reduce the lung cancer mortality in the screened popula-tion. The study was launched in September 2002 and
enrollment closed in February 2004. Over 50,000 current
or former smokers aged 55–74, without prior cancer history
within the past 5 years, were enrolled. Participants were
randomized into the low-dose CT arm or chest X-ray arm.
Baseline screening is followed by repeat screening annually
for 2 years. Test results are mailed to the participant and
their physician, who determines if follow-up tests or
consultations are needed. Participants are followed over a
course of 8 years using annual health questionnaires. Some
centers also collect blood, urine and/or sputum for future
lung cancer biomarker studies. Several additional questions
being addressed by the NLST include all cause mortality,
stage of lung cancer at diagnosis, the cost-effectiveness of
screening, what follow-up tests are done for a positive result
and how screening affects the quality of life and smoking
behavior of screened individuals. Results are expected to be
released in 2009–2010 (www.cancer.gov).
Another multi-center RCT, the NELSON Trial, was
launched in 2003 in the Netherlands and Belgium. The
purpose of the study is to compare lung cancer mortality in
high-risk patients screened with chest CT to those who
receive no screening at all.37 Participants are enrolled
via population-based recruitment rather than volunteer-
based recruitment. Initial recruitment is based on a
questionnaire focused on general health, alcohol consump-
tion, physical exercise, cancer history, a family history of
lung cancer, body weight and height, education and their
opinion on screening programs in general. As of October
2005, over 15,000 current and former smokers aged 50–75
years have been enrolled and roughly 4000 participants
recruited from the Danish trial will be pooled into the
analysis. It is estimated that approximately 17,300–27,900
participants will be required to demonstrate a 20–25%
reduction in lung cancer mortality 10 years after randomiza-
tion, with a power of 80%. This represents the only trial in
which the control arm does not undergo any form of
screening.Summary
Currently, there are at least four available guidelines on
lung cancer screening (see Table 1).38–41 Authoritative
bodies either do not advocate lung cancer screening or if
screening is to be undertaken, they recommend that it
should be within the context of a well-designed trial. The US
Preventative Task Force states that there is insufficient
evidence for or against screening.
In order for screening to be truly effective, it must
demonstrate a decrease in the clinical stage of the disease
and more importantly, death attributable to the disease.
A percentage of pulmonary nodules detected by screening
will ultimately prove to be benign, indolent or clinically
insignificant tumors. Therefore, it is important to consider
what population of patients to screen. It is unclear what
defines ‘‘high risk’’. Should screening only encompass those
deemed high risk? Prior studies such as the NCI sponsored
investigation in the 1970s recruited only males. Although
recent studies have now included females, the defined
smoking history that would place one at high risk varied
among different studies. In addition, screened participants
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Table 1 Current recommendations/guidelines.36–39
Society of Thoracic Radiology Lung cancer screening with CT is not advocated
American Cancer Society If screening is to be performed, this should only be done in centers with experience in testing,
diagnosis and follow-up. An informed decision of those at risk is of utmost importance
US Preventative Task Force
(USPSTF)
There is insufficient evidence for or against lung cancer screening with low-dose CT, chest
X-ray, and/or sputum cytology
American College of Chest
Physicians (ACCP)
Lung cancer screening with chest X-ray or sputum cytology is not advocated. The use of low-
dose CT is not recommended except in the context of a well-designed clinical trial
Lung cancer screening in 2008: Review and update 7were mostly current or former smokers recruited on a
voluntary basis and therefore, would not represent the
overall population demographics that a screening program
might include. Increased understanding of the preclinical
phase of disease and the implementation of complementary
imaging modalities such as PET scan, autofluorescent
bronchoscopy and genomic platforms as biomarkers of
disease may assist in further classifying the high-risk
individual.
Another question pertains to the follow-up of patients
testing positive on screening. The Lung Screening Study,
which paved the way for the NLST, demonstrated that the
number of participants who returned for repeat screening,
or compliance rate, was less for those who tested positive
than those who tested negative.42 Therefore, how are we to
assure that adequate follow-up is performed for these
patients, especially if mass screening is undertaken?
Thus far, efforts at lung cancer screening using low-dose
CT have resulted in the detection of early stage disease but
not an obvious improvement in the disease-specific mortal-
ity rate. There are many limitations to screening that
include inherent biases such as lead time bias, length time
bias and overdiagnosis bias. In addition, the enhanced
detection of early stage disease by CT is also accompanied
by detection of benign nodules that eventually may lead to
further testing and/or surgical interventions that carry risk,
morbidity and mortality. Hence, the jury is still out and the
hope is that the ongoing RCTs will shed light on the utility
and potential benefit of lung cancer screening.Main points Screening with low-dose CT detects more early stage lung
cancer than chest X-ray or sputum analysis. However, a
concomitant decrease in late stage disease or decreased
mortality has not been observed despite improved
identification of early stage disease. Lung cancer screening studies that measure survival are
influenced by multiple biases such as lead time bias,
length time bias and overdiagnosis bias. The enhanced detection of nodules can also result in the
discovery of ‘‘pseudodisease’’ which may be accompa-
nied by risks such as unnecessary testing and surgeries,
cost and psychological burden. Lung cancer screening remains a highly debated topic.
Previous data have been garnered from cohort studies.
The medical community is certainly awaiting the results
of ongoing RCTs that may provide the final verdict on lung
cancer screening.Useful links
American College of Chest Physicians (ACCP): The Diagnosis
and Management of Lung Cancer http://www.chestnet.org/
education/guidelines/currentGuidelines.php
American Thoracic Society (ATS): Cigarette smoking
and health http://www.thoracic.org/sections/publications/
statements/pages/archive/504.html
American Cancer Society http://www.cancer.org/docroot/
home/index.aspAppendix. Questions for lung cancer screening
paper:1. When considering lung cancer, which of the following
statements is true?
a. Lung cancer is the leading cause of cancer deaths in
men but not in women.
b. Only about 10 to 15% of lungs cancers are small cell
cancers.
c. Early detection has already improved 1 and 5 years
lung cancer survival.
d. Most patients are symptomatic early in their episode
of lung cancer.
2. Studies of screening for lung cancer have included the
following modalities and results:
a. Routine chest X-rays increased identification of
resectable tumors and reduced lung cancer mortality.
b. The addition of screening sputum cytology to screen-
ing chest X-ray further reduced lung cancer mortality.
c. Helical CT screening can increase lung cancer detec-
tion rates.
d. Helical CT screening is very specific for lung cancer.
E.g. identifies few benign lesions.
3. Debate surrounding CT screening for lung cancer focuses
on the following clinical issues:
a. The size of the primary tumor (especially non-small
cell) is directly related to the likelihood of metastases
at detection.
b. Identifying small tumors by CT clearly results in
identification of lung cancer at an earlier Stage.
c. Some of the early evidence that appeared to be very
convincing for the advantage of CTscreening was done
in observational rather than randomized control trial
studies.
d. More recent data also demonstrates discovery of more
resectable tumors and leads to reduced mortality at 1
and 5 years.
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the following should be true (check all that are correct)
a. The disease must result in great expense for indivi-
duals with the condition, especially for rare diseases.
b. The condition needs to be identifiable prior to the
onset of clinical symptoms that would be expected to
lead to evaluation and diagnosis.
c. Earlier diagnosis should improve outcomes.
d. Screening tests must be inexpensive and very specific.5. When considering clinically important cancers, which of
the following statements is true?
a. No lung cancer is ever clinically indolent or unrelated
to patient survival.
b. Earlier diagnosis always has benefits for the patient.
c. As many as 1 in 4 Stage 1 lung cancers may be indolent.
d. Lung cancer screening has no risks.References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer
statistics, 2007. CA Cancer J Clin 2007;57:43–66.
2. Kubik AK, Parkin DM, Zatloukal P. Czech study on lung cancer
screening: post-trial follow-up of lung cancer deaths up to year
15 since enrollment 10. Cancer 2000;89:2363–8.
3. Frost JK, Ball Jr WC, Levin ML, et al. Early lung cancer
detection: results of the initial (prevalence) radiologic and
cytologic screening in the Johns Hopkins study. Am Rev Respir
Dis 1984;130:549–54.
4. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB,
Martini N. Early lung cancer detection: results of the initial
(prevalence) radiologic and cytologic screening in the Memorial
Sloan-Kettering study 11. Am Rev Respir Dis 1984;130:555–60.
5. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer
detection: results of the initial (prevalence) radiologic and
cytologic screening in the Mayo Clinic study. Am Rev Respir Dis
1984;130:561–5.
6. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung
cancer. A critique of the Mayo Lung Project. Cancer 1991;67:
1155–64.
7. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer
with mobile spiral computed tomography scanner. Lancet
1998;351:1242–5.
8. Henschke CI. Early lung cancer action project: overall design
and findings from baseline screening. Cancer 2000;89:2474–82.
9. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer
with low-dose helical computed tomography: anti-lung cancer
association project 15. J Clin Oncol 2002;20:911–20.
10. Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung cancer
with low-dose spiral computed tomography 16. Am J Respir Crit
Care Med 2002;165:508–13.
11. Heyneman LE, Herndon JE, Goodman PC, Patz Jr EF. Stage
distribution in patients with a small (o or ¼ 3 cm) primary
nonsmall cell lung carcinoma. Implication for lung carcinoma
screening 1. Cancer 2001;92:3051–5.
12. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening
with CT: Mayo Clinic experience. Radiology 2003;226:756–61.
13. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW,
Smith JP, Miettinen OS. Survival of patients with stage I lung
cancer detected on CTscreening. N Engl J Med 2006;355:1763–71.
14. Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G,
Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of
survival and implications for screening. Cancer 2000;89:2334–44.
15. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg
CB. Computed tomography screening and lung cancer out-
comes. J Am Med Assoc 2007;297:953–61.16. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung
cancer risk among smokers. J Natl Cancer Inst 2003;95:470–8.
17. Bach PB, Elkin EB, Pastorino U, et al. Benchmarking lung cancer
mortality rates in current and former smokers. Chest 2004;
126:1742–9.
18. Cronin KA, Gail MH, Zou Z, Bach PB, Virtamo J, Albanes D.
Validation of a model of lung cancer risk prediction among
smokers. J Natl Cancer Inst 2006;98:637–40.
19. Obuchowski NA, Graham RJ, Baker ME, Powell KA. Ten criteria
for effective screening: their application to multislice CT
screening for pulmonary and colorectal cancers. Am J Roent-
genol 2001;176:1357–62.
20. Schoder H, Gonen M. Screening for cancer with PETand PET/CT:
potential and limitations 1. J Nucl Med 2007;48(Suppl. 1):
4S–18S.
21. Black WC. Computed tomography screening for lung cancer:
review of screening principles and update on current status.
Cancer 2007;110:2370–84.
22. Yankelevitz DF, Kostis WJ, Henschke CI, et al. Overdiagnosis in
chest radiographic screening for lung carcinoma: frequency.
Cancer 2003;97:1271–5.
23. Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung
cancer screening experience: CT appearance, growth rate,
location, and histologic features of 61 lung cancers. Radiology
2007;242:555–62.
24. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening
with CT: Mayo Clinic experience. Radiology 2003;226:756–61.
25. Dammas S, Patz Jr EF, Goodman PC. Identification of small lung
nodules at autopsy: implications for lung cancer screening and
overdiagnosis bias. Lung Cancer 2001;33:11–6.
26. Manser RL, Dodd M, Byrnes G, Irving LB, Campbell DA. Incidental
lung cancers identified at coronial autopsy: implications for
overdiagnosis of lung cancer by screening. Respir Med 2005;
99:501–7.
27. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung
cancer: five-year prospective experience. Radiology 2005;235:
259–65.
28. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer
action project: initial findings on repeat screenings. Cancer
2001;92:153–9.
29. Crestanello JA, Allen MS, Jett JR, et al. Thoracic surgical
operations in patients enrolled in a computed tomographic
screening trial 1. J Thorac Cardiovasc Surg 2004;128:254–9.
30. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe
NR. Lung cancer screening with helical computed tomography in
older adult smokers: a decision and cost-effectiveness analysis
1. J Am Med Assoc 2003;289:313–22.
31. Chirikos TN, Hazelton T, Tockman M, Clark R. Screening for lung
cancer with CT: a preliminary cost-effectiveness analysis. Chest
2002;121:1507–14.
32. Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost-
effectiveness of low-dose CT screening for lung cancer: prelimin-
ary results of baseline screening. Chest 2003;124:614–21.
33. Diederich S, Lenzen H. Radiation exposure associated with
imaging of the chest: comparison of different radiographic
and computed tomography techniques. Cancer 2000;89:
2457–60.
34. Brenner DJ, Hall EJ. Computed tomography—an increasing
source of radiation exposure 1. N Engl J Med 2007;357:
2277–84.
35. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies
of mortality of atomic bomb survivors. Report 13: solid cancer
and noncancer disease mortality: 1950–1997. Radiat Res 2003;
160:381–407.
36. Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al. Early lung
cancer detection using spiral computed tomography and
positron emission tomography. Am J Respir Crit Care Med 2005;
171:1378–83.
ARTICLE IN PRESS
Lung cancer screening in 2008: Review and update 937. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based
selection from the general population in a screening trial:
selection criteria, recruitment and power for the Dutch–Belgian
randomised lung cancer multi-slice CT screening trial (NELSON)
1. Int J Cancer 2007;120:868–74.
38. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society
guidelines for the early detection of cancer, 2006. CA Cancer J
Clin 2006;56:11–25.
39. US Preventive Services Task Force. Lung cancer screening:
recommendation statement. Ann Intern Med 2004;140:
738–9.40. Bach PB, Silvestri GA, Hanger M, Jett JR. Screening for lung
cancer: ACCP evidence-based clinical practice guidelines (2nd
edition). Chest 2007;132:69S–77S.
41. Aberle DR, Gamsu G, Henschke CI, Naidich DP, Swensen SJ. A
consensus statement of the society of thoracic radiology:
screening for lung cancer with helical computed tomography.
J Thorac Imaging 2001;16:65–8.
42. Gohagan JK, Marcus PM, Fagerstrom RM, et al. Final results of
the lung screening study, a randomized feasibility study of spiral
CT versus chest X-ray screening for lung cancer. Lung Cancer
2005;47:9–15.
